Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lactoserum · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| lactoserum | DRUG | - |
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...
Lactoserum is an investigational small molecule being developed by Sanofi for hygiene purposes. It is in Phase 3 clinical development, with four completed trials studying its acceptability and compatibility in hygiene products. The trials enrolled a total of 160 healthy volunteers, primarily in Brazil.
Sanofi (ticker: SNY) is developing lactoserum. The company has conducted four Phase 3 clinical trials for this hygiene product, all of which are completed. These trials were run in Brazil and involved healthy volunteers.
Lactoserum is in Phase 3 clinical development. All four of its clinical trials are completed, with no active trials currently ongoing. The trials were uncontrolled and not randomized or double-blinded, and they enrolled a total of 160 participants.
Lactoserum has four completed Phase 3 trials: NCT00370162 and NCT00397527 studied acceptability of Dermacyd products with lactoserum in women, while NCT00371852 and NCT00380991 studied topic compatibility in all adults. All trials were conducted in Brazil with healthy volunteers.
Lactoserum is investigational and still in clinical development. It is in Phase 3 trials, but no approval status has been reported. The four completed trials focused on hygiene product acceptability and compatibility, not on efficacy for a specific medical condition.